NCT07343544

Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.

Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: AB Biotics, SA · Industry
• Sex: Female
• Age: 35 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging. The study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®). Safety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.

Detailed description

This clinical study is designed to evaluate the effects and safety of a topical cosmetic product formulated with postbiotic ingredients in adult women presenting visible signs of skin aging. The product contains Bifida ferment extract and Pediococcus ferment extract, selected for their scientifically supported properties in enhancing skin barrier function, reducing oxidative stress, and improving overall skin appearance. The study is a prospective, single-center, intra-subject controlled clinical trial with a total duration of three months. Forty-five Caucasian women aged between 35 and 60 years will be enrolled. Participants must present mild to moderate facial wrinkles and/or pigmentation spots and will be evenly distributed between sensitive and normal skin types. Inclusion and exclusion criteria are clearly defined to ensure participant safety and data reliability. Participants will apply 1 ml of the cosmetic product twice daily (morning and evening) to clean, dry facial skin. The study includes four scheduled visits: pre-selection, baseline (T0), (T1), 1 month (T2), 2 months (T3), and 3 months (T4). During these visits, clinical assessments will be conducted using validated dermatological scales (Skin Aging Atlas and Glogau scale) and non-invasive instrumental evaluations. Instrumental assessments include AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®. Photographic documentation will be performed using Visiofaceae, capturing standardized facial images at each visit. Subjective perception will be evaluated through structured questionnaires administered at T1, T2, T3, and additionally at day 7. These questionnaires assess product appreciation, organoleptic characteristics, absorption, residue, and perceived effects on skin condition. Safety monitoring includes systematic documentation of all adverse events (AEs). The expected incidence of SAEs related to the product is below 1%. All safety data will be recorded in the Case Report Form (CRF) and analyzed according to Good Clinical Practice (GCP) guidelines. Participants will be compensated for travel and related expenses. Statistical analysis will be conducted using RStudio software. The study is powered to detect significant changes in skin aging parameters, with a sample size of 45 participants calculated to achieve 80% statistical power. Analysis will include descriptive statistics, repeated measures ANOVA, and mixed model repeated measures (MMRM) to evaluate treatment effects over time. This study aims to provide robust clinical evidence supporting the efficacy and safety of a novel cosmetic formulation based on postbiotic technology, contributing to the development of innovative anti-aging skincare solutions.

Conditions

• Skin
• Skin Ageing
• Fine Lines
• Face Aging/Photo Aging of Moderate Grade
• Face Skin Photoaging

Interventions

Type	Name	Description
OTHER	Active cream	Active facial cream with postbiotics.

Timeline

• Start date: 2026-02-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2026-01-15
• Last updated: 2026-01-15